Mechanisms and Therapeutic Use of CR3 Signaling in Modulating Autoimmunity

CR3 信号传导调节自身免疫的机制和治疗用途

基本信息

批准号：
8049713
负责人：
EDWARD M BEHRENS
金额：
$ 13.39万
依托单位：
CHILDREN'S HOSP OF PHILADELPHIA
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-04-01 至 2014-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8049713
关键词：
Address Adherence Adhesions Animal Model Antigen Presentation Antigen-Presenting Cells Antigens Apoptotic Autoantigens Autoimmune Diseases Autoimmunity B-Lymphocytes Biology Cell physiology Cells Dendritic Cells Dendritic cell activation Disease Event Experimental Autoimmune Encephalomyelitis Exposure to Goals Immune response Immune system Immunization Immunology Injection of therapeutic agent Integrins Investigation Knowledge LCP2 gene Lead Learning Ligation Macrophage-1 Antigen Mediating Mitogen-Activated Protein Kinases Molecular Molecular Probes Monoclonal Antibodies Peptides Phosphorylation Receptor Cell Research Research Personnel Rheumatism Role Signal Transduction Staging Systemic Lupus Erythematosus T-Cell Activation T-Lymphocyte Testing Therapeutic Uses cytokine experience immune function in vivo interest novel oligodendrocyte-myelin glycoprotein pathogen prevent programs research study response rituximab success

项目摘要

DESCRIPTION (provided by applicant): Complement Receptor 3 (CR3) is an apoptotic cell receptor found on dendritic cells (DCs), the most potent antigen presenting cell of the immune system. We demonstrated that activation of CR3 on DCs using a monoclonal antibody modulates DC cytokine expression and inhibits their antigen presentation capacity. The exact mechanism through which CR3 mediates its effects of DCs is still unknown, and the ability of CR3 ligated DCs to induce tolerance in vivo needs exploration. RELEVANCE: We propose to learn the mechanisms of Complement Receptor 3 mediated suppression of dendritic cells function, and to harness this knowledge to treat autoimmunity. This proposal aims to emulate the success of the biologies, such as Rituximab or Abatacept, that were developed from the knowledge provided by basic immunology research. The experience gained in this proposal will direct efforts toward using CR3 mediated tolerance at the bedside in rheumatic diseases such as MS and SLE.

描述（由申请人提供）：补体受体3（CR3）是在树突状细胞（DC）上发现的凋亡细胞受体，树突状细胞是免疫系统中最有效的抗原呈递细胞。我们证明，使用单克隆抗体激活 DC 上的 CR3 可调节 DC 细胞因子的表达并抑制其抗原呈递能力。 CR3介导DC作用的确切机制仍不清楚，CR3连接的DC在体内诱导耐受的能力需要探索。相关性：我们建议了解补体受体 3 介导的树突状细胞功能抑制机制，并利用这些知识来治疗自身免疫性疾病。该提案旨在效仿利妥昔单抗或阿巴西普等生物制剂的成功，这些生物制剂是根据基础免疫学研究提供的知识开发出来的。该提案中获得的经验将指导在床边使用 CR3 介导的耐受性治疗 MS 和 SLE 等风湿性疾病。